A comparative double-blind randomised study of single dose fosfomycin trometamol with trimethoprim in the treatment of urinary tract infections in general practice

Robert Harvard Davis*, T. C. O’Dowd, W. Holmes, J. Smail, R. C.B. Slack

*Corresponding author for this work

    Research output: Contribution to journalArticlepeer-review

    18 Citations (Scopus)

    Abstract

    A double-blind, double-dummy trial comparing a single dose treatment with fosfomycin trometamol (FT, 3 g) versus trimethoprim (TMP, 200 mg) was carried out in women with uncomplicated urinary tract infections. From 51 clinically evaluable patients, 44 were bacteriologically assessable at the 6-week follow-up. The results were as follows in the FT group (n = 22): eradiction in 17 (77.3%); recurrence in 2 (9%); reinfection in 2 (9%), and persistence in 1 (4.5%). For the TMP group (n = 22) the results were: eradication in 12 (54.5%); recurrence in 1 (4.5%); reinfection in 1 (4.5%), and persistence in 8 (33.3%). There were no significant adverse events reported with either agent.

    Original languageEnglish
    Pages (from-to)34-36
    Number of pages3
    JournalChemotherapy
    Volume36
    DOIs
    Publication statusPublished - 1990

    Keywords

    • Fosfomycin trometamol
    • Trimethoprim
    • Urinary tract infection, female

    Fingerprint

    Dive into the research topics of 'A comparative double-blind randomised study of single dose fosfomycin trometamol with trimethoprim in the treatment of urinary tract infections in general practice'. Together they form a unique fingerprint.

    Cite this